Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: Results from an updated systematic review and meta-analysis

European Journal of Cancer

Volumn 49, Issue 9, 2013, Pages 2086-2092

  Zhu, Jianhong ^a   Zheng, Yayuan ^a   Zhou, Zhikun ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Bone metastasis; Breast cancer; Clodronate; Meta analysis; Overall survival

Indexed keywords

CLODRONIC ACID;

BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER SURVIVAL; DRUG EFFICACY; EARLY CANCER; HUMAN; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS;

EID: 84877704242     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.01.021     Document Type: Article

References (28)

1. D.M. Parkin, F. Bray, and J. Ferlay Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
3. A. VanderWalde, and A. Hurria Aging and osteoporosis in breast and prostate cancer CA Cancer J Clin 61 2011 139 156
4. G.D. Roodman Mechanisms of bone metastasis N Engl J Med 350 2004 1655 1664
5. O. Bock, and D. Felsenberg Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice Clin Interv Aging 3 2008 279 297
6. B.E. Hillner, J.N. Ingle, and J.R. Berenson American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel J Clin Oncol 18 2000 1378 1391
7. A.H. Paterson, S.J. Anderson, and B.C. Lembersky Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial Lancet Oncol 13 2012 734 742
8. I.J. Diel, A. Jaschke, and E.F. Solomayer Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up Ann Oncol 19 2008 2007 2011
9. T. Powles, A. Paterson, and E. McCloskey Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] Breast Cancer Res 8 2006 R13
10. T. Saarto, C. Blomqvist, and P. Virkkunen Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial J Clin Oncol 19 2001 10 17
11. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med 6 2009 e1000100
12. A.R. Jadad, R.A. Moore, and D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
13. J.P.T. Higgins, S. Green Cochrane Collaboration Cochrane handbook for systematic reviews of interventions 2008 Wiley-Blackwell Chichester, England; Hoboken, NJ
14. T.C. Ha, and H. Li Meta-analysis of clodronate and breast cancer survival Br J Cancer 96 2007 1796 1801
15. I.J. Diel, E.F. Solomayer, and S.D. Costa Reduction in new metastases in breast cancer with adjuvant clodronate treatment N Engl J Med 339 1998 357 363
16. T. Saarto, L. Vehmanen, and P. Virkkunen Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients Acta Oncol 43 2004 650 656
17. G.R. Mundy Realising the potential of anti-host cell therapy Cancer Today Suppl. 1 2004 6 8
18. S.M. Zeisberger, B. Odermatt, and C. Marty Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach Br J Cancer 95 2006 272 281
19. S. Hafeman, C. London, and R. Elmslie Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs Cancer Immunol Immunother 59 2010 441 452
20. S. Gazzaniga, A.I. Bravo, and A. Guglielmotti Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft J Invest Dermatol 127 2007 2031 2041
21. A.M. Guth, S.D. Hafeman, and S.W. Dow Depletion of phagocytic myeloid cells triggers spontaneous T cell- and NK cell-dependent antitumor activity Oncoimmunology 1 2012 1248 1257
22. T. Ziebart, A. Pabst, and M.O. Klein Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro Clin Oral Investig 15 2011 105 111
23. D. Ribatti, N. Maruotti, and B. Nico Clodronate inhibits angiogenesis in vitro and in vivo Oncol Rep 19 2008 1109 1112
24. P. Fournier, S. Boissier, and S. Filleur Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Res 62 2002 6538 6544
25. X. Tang, Q. Zhang, and S. Shi Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells Int J Cancer 126 2010 90 103
26. S. Boissier, M. Ferreras, and O. Peyruchaud Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases Cancer Res 60 2000 2949 2954
27. L. Dalle Carbonare, M.T. Valenti, and G. Azzarello Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells Mol Cell Endocrinol 240 2005 23 31
28. R. Verdijk, H.R. Franke, and F. Wolbers Differential effects of bisphosphonates on breast cancer cell lines Cancer Lett 246 2007 308 312